Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.0112.01%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 350.40K | 460.10K | 657.60K | 617.10K | 723.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 350.40K | 460.10K | 657.60K | 617.10K | 723.90K |
| Cost of Revenue | 2.11M | 2.19M | 1.79M | 1.96M | 1.81M |
| Gross Profit | -1.76M | -1.73M | -1.13M | -1.34M | -1.09M |
| SG&A Expenses | 4.32M | 3.95M | 3.52M | 2.61M | 1.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.44M | 6.14M | 5.31M | 4.56M | 2.90M |
| Operating Income | -6.09M | -5.68M | -4.65M | -3.95M | -2.17M |
| Income Before Tax | -6.73M | -6.43M | -5.42M | -4.76M | -3.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.73 | -6.43 | -5.42 | -4.76 | -3.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 71.50K | 59.20K | 21.50K | -- | -- |
| Net Income | -6.66M | -6.37M | -5.40M | -4.76M | -3.03M |
| EBIT | -6.09M | -5.68M | -4.65M | -3.95M | -2.17M |
| EBITDA | -6.09M | -5.68M | -4.65M | -3.94M | -2.16M |
| EPS Basic | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 1.68B | 1.68B | 1.68B | 1.68B | 1.68B |
| Average Diluted Shares Outstanding | 1.68B | 1.68B | 1.68B | 1.68B | 1.68B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |